Establishment of reproducible xenotransplantation model of T cell acute lymphoblastic leukemia in NOD/SCID mice

Abstract

T cell acute lymphoblastic leukemia (T-ALL) is an aggressive leukemia. However the poor prognosis and low morbidity restrict further analysis of the disease. Therefore there is an increasing demand to develop animal models for identifying novel therapeutic approaches. In this study, we inoculated the anti-mouse CD122 monoclonal antibody conditioned NOD/SCID mice with the leukemia cells from 9 T-ALL patients and 1 cell line via the tail vein. Four of the 9 patients and the cell line were successfully engrafted. Flow cytometry detected high percentage of human CD45⁺ cells in recipient mice. Immunohistochemistry showed infiltration of human CD45⁺ cells in different organs. Serial transplantation was also achieved. In vivo drug treatment showed that dexamethasone could extend survival, which was consistent with clinical observation. These results demonstrated that we successfully established 5 xenotransplantation models of T-ALL in anti-mCD122 mAb conditioned NOD/SCID mice, which recapitulated the characteristics of original disease.

Keywords

T cell acute lymphoblastic leukemia / xenotransplantation / NOD/SCID mice / in vivo

References

[1] VogelsteinB., KinzlerK.W.. Cancer genes and the pathways they control. Nat Med, 2004, 10(8): 789-799

[2] BoucheixC., DavidB., SebbanC., et al.. Immunophenotype of adult acute lymphoblastic leukemia, clinical parameters, and outcome: an analysis of a prospective trial including 562 tested patients (LALA87). French Group on Therapy for Adult Acute Lymphoblastic Leukemia. Blood, 1994, 84(5): 1603-1612

[3] AnninoL., VegnaM.L., CameraA., et al.. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood, 2002, 99(3): 863-871

[4] LapidotT., FajermanY., KolletO.. Immune-deficient SCID and NOD/SCID mice models as functional assays for studying normal and malignant human hematopoiesis. J Mol Med (Berl), 1997, 75(9): 664-673

[5] ShultzL.D., IshikawaF., GreinerD.L.. Humanized mice in translational biomedical research. Nat Rev Immunol, 2007, 7(2): 118-130

[6] BosmaM.J., CarrollA.M.. The SCID mouse mutant: definition, characterization, and potential uses. Annu Rev Immunol, 1991, 9: 323-350

[7] CesanoA., HoxieJ.A., LangeB., et al.. The severe combined immunodeficient (SCID) mouse as a model for human myeloid leukemias. Oncogene, 1992, 7(5): 827-836

[8] ShultzL.D., SchweitzerP.A., ChristiansonS.W., et al.. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol, 1995, 154(1): 180-191

[9] WangJ.C., LapidotT., CashmanJ.D., et al.. High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase. Blood, 1998, 91(7): 2406-2414

[10] CoxC.V., EvelyR.S., OakhillA., et al.. Characterization of acute lymphoblastic leukemia progenitor cells. Blood, 2004, 104(9): 2919-2925

[11] LavauC., LuoR.T., DuC., et al.. Retrovirus-mediated gene transfer of MLL-ELL transforms primary myeloid pro genitors and causes acute myeloid leukemias in mice. Proc Natl Acad Sci USA, 2000, 97(20): 10984-10989

[12] de GuzmanC.G., WarrenA.J., ZhangZ., et al.. Hematopoietic stem cell expansion and distinct myeloid developmental abnormalities in a murine model of the AML1-ETO translocation. Mol Cell Biol, 2002, 22(15): 5506-5517

[13] LiS., IlariaR.L.Jr, MillionR.P., et al.. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med, 1999, 189(9): 1399-1412

[14] DobsonC.L., WarrenA.J., PannellR., et al.. The mll-AF9 gene fusion in mice controls myeloproliferation and specifies acute myeloid leukaemogenesis. EMBO J, 1999, 18(13): 3564-3574

[15] YuY., BradleyA.. Engineering chromosomal rearrangements in mice. Nat Rev Genet, 2001, 2(10): 780-790

[16] HeisterkampN., JensterG., KioussisD., et al.. Human bcr-abl gene has a lethal effect on embryogenesis. Transgenic Res, 1991, 1(1): 45-53

[17] YergeauD.A., HetheringtonC.J., WangQ., et al.. Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene. Nat Genet, 1997, 15(3): 303-306

[18] AplanP.D., JonesC.A., ChervinskyD.S., et al.. An scl gene product lacking the transactivation domain induces bony abnormalities and cooperates with LMO1 to generate T-cell malignancies in transgenic mice. EMBO J, 1997, 16(9): 2408-2419

[19] AillesL.E., GerhardB., KawagoeH., et al.. Growth characteristics of acute myelogenous leukemia progenitors that initiate malignant hematopoiesis in nonobese diabetic/severe combined immunodeficient mice. Blood, 1999, 94(5): 1761-1772

[20] LumkulR., GorinN.C., MalehornM.T., et al.. Human AML cells in NOD/SCID mice: engraftment potential and gene expression. Leukemia, 2002, 16(9): 1818-1826

[21] PlasilovaM., ZivnyJ., JelinekJ., et al.. TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors. Leukemia, 2002, 16(1): 67-73

[22] ShultzL.D., LangP.A., ChristiansonS.W., et al.. NOD/LtSz-Rag1null mice: an immunodeficient and radioresistant model for engraftment of human hematolymphoid cells, HIV infection, and adoptive transfer of NOD mouse diabetogenic T cells. J Immunol, 2000, 164(5): 2496-2507

[23] TanakaT., TsudoM., KarasuyamaH., et al.. A novel monoclonal antibody against murine IL-2 receptor beta-chain. Characterization of receptor expression in normal lymphoid cells and EL-4 cells. J Immunol, 1991, 147(7): 2222-2228

[24] EhlS., NueschR., TanakaT., et al.. A comparison of efficacy and specificity of three NK depleting antibodies. J Immunol Methods, 1996, 199(2): 149-153

[25] ShultzL.D., BanuelosS.J., LeifJ., et al.. Regulation of human short-term repopulating cell (STRC) engraftment in NOD/SCID mice by host CD122+ cells. Exp Hematol, 2003, 31(6): 551-558

[26] McKenzieJ.L., GanO.I., DoedensM., et al.. Human short-term repopulating stem cells are efficiently detected following intrafemoral transplantation into NOD/SCID recipients depleted of CD122+ cells. Blood, 2005, 106(4): 1259-1261

[27] LewisI.D., McDiarmidL.A., SamelsL.M., et al.. Establishment of a reproducible model of chronic-phase chronic myeloid leukemia in NOD/SCID mice using blood-derived mononuclear or CD34+ cells. Blood, 1998, 91(2): 630-640

[28] PearceD.J., TaussigD., ZibaraK., et al.. AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. Blood, 2006, 107(3): 1166-1173

[29] BonnetD., BhatiaM., WangJ.C., et al.. Cytokine treatment or accessory cells are required to initiate engraftment of purified primitive human hematopoietic cells transplanted at limiting doses into NOD/SCID mice. Bone Marrow Transplant, 1999, 23(3): 203-209

[30] RomboutsW.J., MartensA.C., PloemacherR.E.. Identification of variables determining the engraftment potential of human acute myeloid leukemia in the immunodeficient NOD/SCID human chimera model. Leukemia, 2000, 14(5): 889-897

[31] NitscheA., JunghahnI., ThulkeS., et al.. Interleukin-3 promotes proliferation and differentiation of human hematopoietic stem cells but reduces their repopulation potential in NOD/SCID mice. Stem Cells, 2003, 21(2): 236-244